Stay updated on FRα Clinical Trial: Mirvetuximab vs. Chemo
Sign up to get notified when there's something new on the FRα Clinical Trial: Mirvetuximab vs. Chemo page.

Latest updates to the FRα Clinical Trial: Mirvetuximab vs. Chemo page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe FORWARD I study record is displayed, detailing the completed Phase 3 comparison of mirvetuximab soravtansine with investigator-selected chemotherapy for eligible patients with advanced ovarian, primary peritoneal, or fallopian tube cancer. The record includes study design and outcomes, participant eligibility, locations, and downloadable study documents.SummaryDifference100%

- Check20 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0. The page continues to show a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check27 days agoChange DetectedA sitewide NIH banner announces updates and FAQs about a transition in terminology from “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check34 days agoChange DetectedThe ClinicalTrials.gov error page's footer revision changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check41 days agoChange DetectedThe site’s displayed revision changes from v3.7.0 to v3.7.1, while the study record remains inaccessible behind a 403 error.SummaryDifference0.2%

- Check62 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the detailed study record content with a minimal error screen.SummaryDifference18%

Stay in the know with updates to FRα Clinical Trial: Mirvetuximab vs. Chemo
Enter your email address, and we'll notify you when there's something new on the FRα Clinical Trial: Mirvetuximab vs. Chemo page.